US Stock MarketDetailed Quotes

RAPP Rapport Therapeutics

Watchlist
  • 11.040
  • -0.740-6.28%
Close Feb 26 16:00 ET
  • 11.040
  • 0.0000.00%
Post 16:00 ET
403.80MMarket Cap-5.62P/E (TTM)

About Rapport Therapeutics Company

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Company Profile

SymbolRAPP
Company NameRapport Therapeutics
Listing DateJun 7, 2024
Issue Price17.00
Founded2022
CEOMr. Abraham N. Ceesay, M.B.A.
MarketNASDAQ
Employees58
Fiscal Year Ends12-31
Address1325 Boylston Street,Suite 401
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02215
Phone1-857-321-8020

Company Executives

  • Name
  • Position
  • Salary
  • Abraham N. Ceesay, M.B.A.
  • Chief Executive Officer and Director
  • 2.42M
  • Cheryl Gault
  • Chief Operating Officer
  • 1.78M
  • Dr. Swamy Yeleswaram, PhD
  • Chief Development Officer
  • --
  • Troy A. Ignelzi
  • Chief Financial Officer
  • 2.13M
  • Dr. Bradley S. Galer, M.D.
  • Chief Medical Officer
  • --
  • Kathy Wilkinson
  • Chief People Officer
  • --
  • David Bredt, M.D.,PhD
  • Chief Scientific Officer and Director
  • --
  • Dr. Steven M. Paul, M.D.
  • Chairman of the Board
  • 568.99K
  • Dr. Reid M. Huber, PhD
  • Director
  • 400.26K
  • Dr. James I. Healy, M.D.,PhD
  • Director
  • --
  • Terry-Ann Burrell, M.B.A.
  • Director
  • --
  • Dr. John M. Maraganore,PhD
  • Director
  • --
  • Dr. Jeffrey K. Tong, PhD
  • Director
  • 55.50K
  • Raymond Kelleher, M.D.,PhD
  • Director
  • --

Trending Stocks

Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More